Cholesterol Drugs May Boost Exercise Gains in Hospitalized Elders, Trial Analysis Suggests

One of the most feared consequences of a hospital stay in later life is not the illness that brought the patient through the doors, but the quiet erosion of independence that follows days spent in bed. Acute hospitalization is now recognized as a critical trigger of functional decline in people over 75, and clinicians have increasingly turned to structured, supervised exercise programs delivered on the ward to counteract it. A new secondary analysis of a randomized controlled trial, published in European Geriatric Medicine, adds an unexpected pharmacological twist to this story: it suggests that the millions of older adults already taking statins may respond to hospital-based exercise at least as well as, and possibly slightly better than, those who are not on the cholesterol-lowering drugs.

The study, led by J. F. Trujillo-Rivera and M. Gutiérrez-Valencia with senior author N. Martínez-Velilla and colleagues based at Navarrabiomed and the Hospital Universitario de Navarra in Pamplona, Spain, revisited data from a randomized clinical trial registered as NCT02300896. The original trial had enrolled 310 acutely hospitalized patients aged over 75, with an average age of 87 and a majority of women at 58.7 percent of the sample. Participants were assigned either to a supervised multicomponent exercise program delivered during their hospital admission or to standard hospital care. The team behind the new analysis asked a deceptively simple question: does taking a statin change how much a very old, acutely ill patient gains from exercise?

The question matters because statins occupy an ambivalent place in geriatric medicine. On one hand, these HMG-CoA reductase inhibitors are among the most widely prescribed drugs in the world, valued for cardiovascular prevention and increasingly discussed for so-called pleiotropic effects on inflammation, oxidative stress and immunomodulation. On the other hand, statins have long carried a reputation for muscle-related side effects, ranging from myalgia to, rarely, rhabdomyolysis, and some observational studies have linked statin use to lower physical activity, reduced exercise capacity and weaker physical performance in older people. If statins truly blunted the muscle’s adaptive response to training, prescribing them to frail elders who need every gram of muscle they can keep would be a genuine clinical dilemma.

Previous research had hinted at a more optimistic picture. A 2012 study in Age Ageing found that older people on statins showed better outcomes during inpatient rehabilitation, and a 2018 trial in dyslipidemic older adults reported that combining statin therapy with exercise training improved functional status more than exercise alone. Mechanistic work in animal and human muscle has suggested that statins and exercise may interact in complex ways, with some evidence of attenuated mitochondrial responses in certain contexts and other evidence of anti-inflammatory benefits that could support recovery. The heterogeneity of these findings was a central theme of a 2023 National Institutes of Health workshop on optimizing exercise responses in older adults, which called for better understanding of why individuals differ in how they respond to training. The new Spanish analysis speaks directly to that agenda in one of the most vulnerable populations imaginable: patients in the middle of an acute hospital admission.

The primary outcome of the analysis was the change in the Barthel Index, a widely used measure of independence in activities of daily living that scores functions such as feeding, bathing, dressing, continence, toileting, transferring, mobility and stair climbing. The index is particularly meaningful in geriatric hospital care because it captures the practical abilities that determine whether a patient can return home or will need institutional support. Prior work in stroke patients has established thresholds for the minimal clinically important difference of the Barthel Index, giving clinicians a benchmark for judging whether a measured change is large enough to matter in daily life rather than merely registering as a statistical blip.

The headline result is reassuringly straightforward: exercise worked, and it worked regardless of statin use. Patients who received the supervised multicomponent program improved their functional outcomes, and this benefit was observed across the cohort whether or not they happened to be taking a statin. In other words, the fundamental message of the original trial, that very old hospitalized patients can and should be exercised even during acute illness, survives the stratification by lipid-lowering therapy. For clinicians who have hesitated to enroll statin users in ward-based exercise programs for fear of provoking muscle damage, the safety data are equally welcome: the researchers observed no statin-related adverse muscle events during the intervention.

Beneath that main finding, however, sits a more provocative one. In exploratory adjusted models, statin users showed a potentially greater improvement in Barthel Index scores than non-users, with a mean difference of 5.58 points and a 95 percent confidence interval of 0.44 to 10.7, yielding a p value of 0.035. The authors themselves are careful to flag that this finding should be interpreted with caution, and the caution is warranted on several grounds. The analysis was secondary and exploratory rather than designed and powered to test the statin question, so the comparison of statin users to non-users is observational in nature even though it sits inside a randomized trial. Patients on statins may differ systematically from those who are not, in cardiovascular burden, in frailty trajectories, in the medications they take alongside them, and in the very reasons they were admitted to hospital. Any of these differences could bias the apparent effect in either direction.

Still, the size of the signal is worth pausing on. A 5.58-point difference on the Barthel Index approaches or exceeds the minimal clinically important difference reported in some patient populations, which would mean the gap is not just statistically detectable but potentially meaningful at the bedside, translating into a patient who can dress independently or walk to the bathroom without help. The confidence interval, while it includes values close to zero, also extends to nearly 11 points, so the data are compatible with effects ranging from trivial to substantial. If the signal is real, plausible biological mechanisms exist to explain it: statins’ anti-inflammatory and antioxidant actions could dampen the catabolic storm of acute illness, their immunomodulatory properties might speed recovery, and emerging research on statins and sarcopenia has explored whether the drugs influence muscle mass and function in aging. The hospital setting, where inflammation and immobilization conspire to strip away function, could theoretically be where such pleiotropic effects are most visible.

The authors are explicit about the practical takeaway, and it is one that resists overinterpretation. Exercise interventions confer functional benefits during acute hospitalization regardless of statin use, they conclude, and the results reinforce the safety of maintaining statins in acutely ill older adults while supporting the implementation of exercise programs on the ward. That framing deliberately avoids recommending statins as an exercise enhancer, a claim the data cannot support. What the study does support is a de-prescribing question answered in the negative: there is no evidence here that continuing a statin during hospitalization undermines a patient’s ability to benefit from rehabilitation, and no evidence that statin users need to be protected from physical activity. In a field where medications are frequently stopped on admission out of generalized caution, that is a consequential null result wrapped around an intriguing positive one.

The broader significance lies in the growing science of response heterogeneity. As the NIH workshop summary and a wave of recent reviews have emphasized, the average treatment effect reported in a trial can conceal enormous individual variation, and modifiers such as coexisting medications, baseline fitness and disease burden determine who benefits most. This analysis is a template for that line of inquiry: take a completed randomized trial with a hard functional endpoint, stratify by a common, modifiable co-treatment, and report both the reassuring main effect and the exploratory interaction with appropriate humility. Whether statins genuinely amplify the functional dividends of ward-based exercise will require dedicated randomized studies designed for that question, ideally with muscle-specific outcomes such as strength, mass and mitochondrial function layered alongside the Barthel Index. Until then, the message for the growing population of very old hospital patients is refreshingly simple: keep moving, keep taking the pills your doctor has judged worthwhile, and expect the exercise to work either way.

Subject of Research: The interaction between statin use and functional response to multicomponent exercise in acutely hospitalized older adults

Article Title: Statin use and functional response to multicomponent exercise in acutely hospitalized older adults: secondary analysis of a randomized trial

Article References: Trujillo-Rivera, J. F., Gutiérrez-Valencia, M., Galbete, A., Chenhuichen, C., Zambom-Ferraresi, F., & Martínez-Velilla, N. (2026). Statin use and functional response to multicomponent exercise in acutely hospitalized older adults: secondary analysis of a randomized trial. European Geriatric Medicine. https://doi.org/10.1007/s41999-026-01615-7

Image Credits: AI Generated

DOI: 10.1007/s41999-026-01615-7

Keywords: statins, exercise therapy, hospitalization, older adults, Barthel Index, functional decline, geriatrics, randomized controlled trial, sarcopenia, physical performance, acute care, rehabilitation